Trials / Withdrawn
WithdrawnNCT04329442
Accelerated PrEP Access for Black MSM and TW
Point of Care PrEP Delivery for Young Black/African American Men Who Have Sex With Men and Young Transgender Women at High Risk for HIV Infection
- Status
- Withdrawn
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- University of Chicago · Academic / Other
- Sex
- Male
- Age
- 18 Years – 24 Years
- Healthy volunteers
- Accepted
Summary
The investigators will pilot-test an accelerated PrEP initiation approach among young high-risk Black/African American (B/AA) men who have sex with men (MSM) and transgender women (YMSM/TW) at the point of care in community contexts.
Detailed description
The study team will provide a free 30-day supply of HIV pre-exposure prophylaxis (PrEP) to young Black MSM and TW identified as PrEP-eligible and interested in taking PrEP to reduce their risk of HIV acquisition. This intervention is intended to assist youth at high risk for HIV acquisition in successfully initiating PrEP use.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Emtricitabine / Tenofovir Disoproxil Oral Tablet | 30 day supply of 200mg tablets |
Timeline
- Start date
- 2020-04-01
- Primary completion
- 2021-07-31
- Completion
- 2021-07-31
- First posted
- 2020-04-01
- Last updated
- 2022-05-19
Source: ClinicalTrials.gov record NCT04329442. Inclusion in this directory is not an endorsement.